While I was out of the country on vacation, Advanced Cell Technology issued four news releases about their ongoing human embryonic stem cell trials. Here is a compilation of what transpired during my absence.
Jan. 25, 2012 -- ACT Announces that Additional Patient with Stargardt's Disease Has Undergone Embryonic Stem Cell Transplantation at UCLA's Jules Stein Eye Institute
Advanced Cell Technology announced the dosing of an additional patient in its Phase 1/2 trial for Stargardt's macular dystrophy using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The patient was treated on Tuesday (Jan. 24) by Steven (Read more...)